"10.1371_journal.pone.0123822","plos one","2015-04-16T00:00:00Z","J P Stellmann; A Neuhaus; N Götze; S Briken; C Lederer; M Schimpl; C Heesen; M Daumer","Institute of Neuroimmunology and MS (INIMS) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany; Trium Analysis Online GmbH, Munich, Germany","Conceived and designed the experiments: JPS AN NG SB CL MS CH MD. Performed the experiments: NG JPS CH. Analyzed the data: JPS CH NG SB MS AN MD CL. Wrote the paper: JPS CH AN SB MD CL.","The authors of this manuscript have the following competing interests: Martin Daumer is an Academic Editor for PeerJ and has invented the free heel running pad. He is also the Director of the Sylvia Lawry Centre for MS Research. He is one of the two managing directors of Trium Analysis Online GmbH, together with Michael Scholz (50% ownership each). Trium is a manufacturer of CTG monitoring systems. Dr. Daumer has served on the scientific advisory board for the EPOSA study; has received funding for travel from ECTRIMS; serves on the editorial board of MedNous; is co-author with Michael Scholz on patents re: Apparatus for measuring activity (Trium Analysis Online GmbH), method and device for detecting a movement pattern (Trium Analysis Online GmbH), device and method to measure the activity of a person (Trium Analysis Online GmbH), co-Author with Christian Lederer of device and method to determine the fetal heart rate from ultrasound signals (Trium Analysis Online GmbH), author of method and device for detecting drifts, jumps and/or outliers of measurement values, coauthor of patent applications with Michael Scholz of device and method to determine the global alarm state of a patient monitoring system, method of communication of units in a patient monitoring system, and system and method for patient monitoring; serves as a consultant for University of Oxford, Imperial College London, University of Southampton, Charite, Berlin, University of Vienna, Greencoat Ltd, Biopartners, Biogen Idec, Bayer Schering Pharma, Roche, and Novartis; and receives/has received research support from the EU-FP7, BMBF, BWiMi, and Hertie Foundation. Christian Lederer and Anneke Neuhaus were employed at the SLC - The Human Motion Institute when the study was performed. Michaela Schimpl were employed at TRIUM GmBH when the study was performed. Sven Briken and Nele Götze have declared that no competing interests exist. Jan-Patrick Stellmann and Christoph Heesen report study, travel and educational grants from Merck-Serono, Biogen-Idec, Teva- Sanofi-Aventis and Bayer-Schering. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","04","J P Stellmann","JPS",8,FALSE,8,3,8,6,TRUE,TRUE,FALSE,0,NA,FALSE
